Evidence map›Paper›PMID 26511795›Full record

ArticleGut2016

The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia.

Tim J Schuijt, Jacqueline M Lankelma, Brendon P Scicluna, Felipe de Sousa e Melo, Joris J T H Roelofs, J Daan de Boer, Arjan J Hoogendijk, Regina de Beer, Alex de Vos, Clara Belzer and 3 more

Abstract read
In one paragraph

Article in Gut, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 514 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
514citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

514 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Indole-3-carboxaldehyde fromGut microbes · 2026
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Journal of bacteriology · 2026
    Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. The gut-lung axis in early life: microbiome-associated mechanisms and clinical relevance.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  19. Article
  20. Article

454 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Tim J SchuijtCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Clinical Chemistry, Hematology and Immunology, Diakonessenhuis Utrecht, The Netherlands.
Jacqueline M LankelmaCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Brendon P SciclunaCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Felipe de Sousa e MeloCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Joris J T H RoelofsDepartment of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
J Daan de BoerCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Arjan J HoogendijkCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Regina de BeerCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Alex de VosCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Clara BelzerLaboratory of Microbiology, Wageningen University, Wageningen, The Netherlands.
Willem M de VosLaboratory of Microbiology, Wageningen University, Wageningen, The Netherlands Department of Bacteriology & Immunology, Helsinki University, Helsinki, Finland.
Tom van der PollCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
W Joost WiersingaCenter for Experimental and Molecular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Medicine, Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-2277-1343

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePneumonia accounts for more deaths than any other infectious disease worldwide. The intestinal microbiota supports local mucosal immunity and is increasingly recognised as an important modulator of the systemic immune system. The precise role of the gut microbiota in bacterial pneumonia, however, is unknown. Here, we investigate the function of the gut microbiota in the host defence against Streptococcus pneumoniae infections.

designWe depleted the gut microbiota in C57BL/6 mice and subsequently infected them intranasally with S. pneumoniae. We then performed survival and faecal microbiota transplantation (FMT) experiments and measured parameters of inflammation and alveolar macrophage whole-genome responses.

resultsWe found that the gut microbiota protects the host during pneumococcal pneumonia, as reflected by increased bacterial dissemination, inflammation, organ damage and mortality in microbiota-depleted mice compared with controls. FMT in gut microbiota-depleted mice led to a normalisation of pulmonary bacterial counts and tumour necrosis factor-α and interleukin-10 levels 6 h after pneumococcal infection. Whole-genome mapping of alveolar macrophages showed upregulation of metabolic pathways in the absence of a healthy gut microbiota. This upregulation correlated with an altered cellular responsiveness, reflected by a reduced responsiveness to lipopolysaccharide and lipoteichoic acid. Compared with controls, alveolar macrophages derived from gut microbiota-depleted mice showed a diminished capacity to phagocytose S. pneumoniae.

conclusionsThis study identifies the intestinal microbiota as a protective mediator during pneumococcal pneumonia. The gut microbiota enhances primary alveolar macrophage function. Novel therapeutic strategies could exploit the gut-lung axis in bacterial infections.

Indexed as

Immunity, MucosalAnimalsAnti-Bacterial AgentsBacterial LoadFecesGastrointestinal MicrobiomeInterleukin-10Macrophages, AlveolarMiceMice, Inbred C57BLPneumonia, PneumococcalSepsisStreptococcus pneumoniaeTranscriptomeTumor Necrosis Factor-alphaUp-RegulationAnti-Bacterial AgentsInterleukin-10Tumor Necrosis Factor-alphaBACTERIAL INFECTIONBACTERIAL PATHOGENESISIMMUNOLOGYINTESTINAL MICROBIOLOGYSEPSIS

Identifiers

PMID26511795
PMCPMC4819612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.